Binimetinib, a MEK inhibitor, showed only a modest PFS benefit [2.8 vs. 1.5, HR 0.62, 95% confidence interval (CI) 0.47–0.80, p < 0.001] in NRAS-mutated melanoma who were treatment naive or had progressed on or after prior immunotherapy, compared with dacarbazine in a randomized phase III clinical trial (NEMO). Here, MAP2K7 is linked to melanoma.